Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background: Multiple pterygium syndrome (MPS) is a genetically heterogeneous rare form of arthrogryposis multiplex congenita characterized by joint contractures and webbing or pterygia, as well as distinctive facial features related to diminished fetal movement. It is divided into prenatally lethal (LMPS, MIM253290) and nonlethal (Escobar variant MPS, MIM 265000) types. Developmental spine deformities are common, may present early and progress rapidly, requiring regular fo llow-up and orthopedic management. Methods: Retrospective chart review and prospective data collection were conducted at three hospital centers. Molecular diagnosis was confirmed with whole exome or whole genome sequencing. Results: This case series describes the clinical features and scoliosis treatment on 12 patients from 11 unrelated families. A molecular diagnosis was confirmed in seven; two with MYH3 variants and five with CHRNG. Scoliosis was present in all but our youngest patient. The remaining 11 patients spanned the spectrum between mild (curve ≤ 25°) and malignant scoliosis (≥50° curve before 4 years of age); the two patients with MYH3 mutations presented with malignant scoliosis. Bracing and serial spine casting appear to be beneficial for a few years; non-fusion spinal instrumentation may be needed to modulate more severe curves during growth and spontaneous spine fusions may occur in those cases. Conclusions: Molecular diagnosis and careful monitoring of the spine is needed in children with MPS.

Details

Title
The Clinical and Genotypic Spectrum of Scoliosis in Multiple Pterygium Syndrome: A Case Series on 12 Children
Author
Dahan-Oliel, Noémi 1   VIAFID ORCID Logo  ; Dieterich, Klaus 2 ; Rauch, Frank 1 ; Bardai, Ghalib 1 ; Blondell, Taylor N 3 ; Gustafson, Anxhela Gjyshi 4 ; Hamdy, Reggie 1 ; Latypova, Xenia 2 ; Shazand, Kamran 4 ; Giampietro, Philip F 5   VIAFID ORCID Logo  ; Harold van Bosse 3   VIAFID ORCID Logo 

 Shriners Hospitals for Children, Montreal, QC H4A 0A9, Canada; [email protected] (F.R.); [email protected] (G.B.); [email protected] (R.H.); Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada 
 Inserm, U1216, Grenoble Institut Neurosciences, Génétique médicale, Université Grenoble Alpes, CHU Grenoble Alpes, 38000 Grenoble, France; [email protected] (K.D.); [email protected] (X.L.) 
 Shriners Hospitals for Children, Philadelphia, PA 19140, USA; [email protected] 
 Shriners Hospitals for Children Headquarters, Tampa, FL 33607, USA; [email protected] (A.G.G.); [email protected] (K.S.) 
 Pediatric Genetics, University of Illinois, Chicago, IL 60612, USA; [email protected] 
First page
1220
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20734425
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2565234632
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.